Harmony Biosciences Holdings (HRMY) Other Operating Expenses (2019 - 2026)

Harmony Biosciences Holdings has reported Other Operating Expenses for 8 years, with the latest figure at $31.7 million in Q1 2026.

• Quarterly Other Operating Expenses rose 3.2% year-over-year to $31.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $161.3 million (up 35.27% YoY) and the FY2025 annual result came in at $189.6 million, up 30.01% from the prior year.
• Other Operating Expenses slipped to $31.7 million in Q1 2026 per HRMY's latest filing, from $49.9 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $51.6 million in Q4 2023 and troughed at $7.6 million in Q1 2022.
• A 5-year average of $28.5 million and a median of $28.5 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses plunged 51.13% in 2022, then jumped 411.76% in 2023.
• Over 5 years, Other Operating Expenses stood at $10.1 million in 2022, then surged by 411.76% to $51.6 million in 2023, then sank by 32.88% to $34.7 million in 2024, then soared by 44.04% to $49.9 million in 2025, then slumped by 36.53% to $31.7 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $31.7 million, $49.9 million, and $29.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.